checkAd
    Startseite > Aktien > Ocuphire Pharma > Nachrichten
    Ocuphire Pharma Aktie
    1,5920
     
    EUR
    -11,36 %
    -0,2040 EUR
    Letzter Kurs 10.05.24 Tradegate
    1,5680
     
    EUR
    2.551 STK
    Geldkurs 10.05.24
    1,6160
     
    EUR
    2.474 STK
    Briefkurs 10.05.24
    ISIN: US67577R1023 · WKN: A2QG4Z · SYM: R3X1 · USA

    Neueste Nachrichten

    Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
    10.05.24 · globenewswire · Ocuphire Pharma
    Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting
    06.05.24 · globenewswire · Ocuphire Pharma
    Ocuphire Pharma to Present at the Aegis Virtual Conference
    03.05.24 · globenewswire · Ocuphire Pharma
    Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
    22.04.24 · globenewswire · Ocuphire Pharma
    First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
    11.04.24 · globenewswire · Ocuphire Pharma
    Ocuphire Announces the U.S. Commercial Launch of RYZUMVl (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
    01.04.24 · globenewswire · Ocuphire Pharma
    Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
    08.03.24 · globenewswire · Ocuphire Pharma
    Ocuphire Pharma to Present in the BIO CEO & Investor Conference
    23.02.24 · globenewswire · Ocuphire Pharma
    Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    15.02.24 · globenewswire · Ocuphire Pharma
    Ocuphire Pharma Strengthens Leadership Team with Key Appointments
    14.02.24 · globenewswire · Ocuphire Pharma
    Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
    05.02.24 · globenewswire · Ocuphire Pharma
    Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    24.01.24 · globenewswire · Ocuphire Pharma